TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19228214
Drug: Lidocaine inferior
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine inferior alveolar nerve block (IANB) with supplementary articaine buccal infiltration (2 mL of articaine 4% with epinephrine 1:100,000)
Study: 19228214
Drug: Dummy buccal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dummy buccal injection
Study: 17255371
Drug: Aprepitant (NK1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (NK1 antagonist)
Study: 15371667
Drug: Cyclosporine (CsA)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (CsA) twice a day (BD group)
Study: 7533998
Drug: Costimulatory stromal
Normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Costimulatory stromal receptors identified in thymuses and TETs
Study: 3065101
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bumetanide and spironolactone (group C, n = 12)
Study: 26833454
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of diacetyl boldine (DAB) serum at night and DAB/TGF‐β1 biomimetic oligopeptide‐68/sunscreen cream in the morning and at noon
Study: 26833454
Drug: 2% and
Normalized name: clindamycin phosphate 12 mg in 1 g / tretinoin 0.25 mg in 1 g TOPICAL GEL [Clindamycin Phosphate 1.2% and Tretinoin 0.025%]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% and 4% hydroquinone cream (HQ)
Study: 24655469
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion protocol with a trigger of hemoglobin ≤ 6 g/dL; transfusion acceptable for hemoglobin 6-8 g/dL and only with evidence of end-organ ischemia for hemoglobin 8-10 g/dL.
Study: 24655469
Drug: Transfusion for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion for hemoglobin 6-8 g/dL
Study: 24655469
Drug: Transfusion for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion for hemoglobin 8-10 g/dL with evidence for end-organ ischemia
Study: 23091107
Drug: Combination query
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination query
Study: 20544311
Drug: Novel pharmacologic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel pharmacologic agents
Study: 15811089
Drug: pioglitazone 15
Normalized name: pioglitazone 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pioglitazone 15 mg
Study: 15811089
Drug: pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pioglitazone 30 mg
Study: 8566605
Drug: Perfusion with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfusion with camostate (synthetic protease inhibitor)
Study: 26486704
Drug: DEC 6
Normalized name: Zodryl DEC 60 Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC 6 mg/kg + ALB 400 mg + IVM 200 μg/kg
Study: 15049459
Drug: DEC 6
Normalized name: Zodryl DEC 60 Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC 6 mg/kg + ALB 400 mg
Study: 22747197
Drug: Cycle ergometry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle ergometry training (30-min once weekly for 6 weeks)
Study: 12971029
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg valdecoxib
Study: 21661426
Drug: Tacrolimus (Tac)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (Tac) in double therapy (plus steroids)
Study: 21661426
Drug: Cyclosporine microemulsion
Normalized name: cyclosporine microemulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine microemulsion (CyA‐me) in triple therapy (plus steroids and azathioprine)
Study: 14693085
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of treatment groups vs control
Study: 2849682
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (18 g/day)
Study: 31506877
Drug: Lung protective
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung protective ventilation (LPV) with a tidal volume of 6 ml/IBW and PEEP of 10 cm H2O
Study: 31506877
Drug: Conventional ventilation
Normalized name: VENTILATOR FILTER,THERMOFLO #6000S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional ventilation (CV) with a tidal volume of 10 ml/IBW and PEEP of 4 cm H2O
Study: 29231549
Drug: Acupoint transcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint transcutaneous electric stimulation combined with conventional intravenous general anesthesia (No.2 group, 50 cases)
Study: 29231549
Drug: Conventional intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intravenous general anesthesia (No.1 group, 48 cases)
Study: 29231549
Drug: Acupoint transcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint transcutaneous electric stimulation combined with conventional intravenous general anesthesia (No.3 group, 48 cases)
Study: 23549132
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical treatment (control)
Study: 21450069
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity screening (alone or in combination with diet)
Study: 18505968
Drug: FEC-P (fluorouracil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC-P (fluorouracil, epirubicin, cyclophosphamide followed by weekly paclitaxel)
Study: 17160915
Drug: Rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg/day and 8 mg/day
Study: 10764700
Drug: 100 U
Normalized name: vitamin E 100 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 U Botulinum toxin (initial injection)
Study: 10764700
Drug: 100 U
Normalized name: vitamin E 100 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 U Botulinum toxin (second injection after 30 days)
Study: 8842654
Drug: Xylitol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol (0.25 g kg‐1 h‐1)
Study: 8842654
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (0.5 g h‐1)
Study: 1569343
Drug: Acid treatment
Normalized name: SALICYLIC ACID 20 mg in 1 mL TOPICAL GEL [Skin Laundry. Clean Slate Exfoliating 2 Salicylic Acid Treatment Gel Cleanser Cleanse Exfoliate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acid treatment of plasma
Study: 2411876
Drug: No speech
Approvals — FDA: no, EMA: no, PMDA: no
Description: No speech therapy
Study: 24401754
Drug: 600 000IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 000IU single intramuscular injection
Study: 23140417
Drug: Menaquinone-4 (MK-4)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menaquinone-4 (MK-4) 420 μg (945 nmol) single dose
Study: 23140417
Drug: Menaquinone-7 (MK-7)
Normalized name: menaquinone 7
DrugBank: Menaquinone 7 (DB13075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menaquinone-7 (MK-7) 420 μg (647 nmol) single dose
Study: 23140417
Drug: Menaquinone-4 (MK-4)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menaquinone-4 (MK-4) 60 μg (135 nmol) consecutive administration for 7 days
Study: 23140417
Drug: Menaquinone-7 (MK-7)
Normalized name: menaquinone 7
DrugBank: Menaquinone 7 (DB13075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menaquinone-7 (MK-7) 60 μg (92 nmol) consecutive administration for 7 days
Study: 17373916
Drug: Rifaximin 1600
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin 1600 mg/day
Study: 16378561
Drug: Fusidic acid
Normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusidic acid gel 1% (one drop, four times daily for one week)
Study: 16378561
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one drop, four times daily for one week)
Study: 16378561
Drug: Fusidic acid
Normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusidic acid gel 1%
Study: 9527749
Drug: Unilateral spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral spinal anaesthesia with 8 mg of hyperbaric bupivacaine 0.5%
Study: 9527749
Drug: Combined sciatico‐femoral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined sciatico‐femoral nerve block with 7 mg kg(‐1) of mepivacaine 2%
Study: 10150352
Drug: Adhesive-sparing moisturizing
Normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adhesive-sparing moisturizing cream, 0.1 mL applied to gloves
Study: 10150352
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no cream)
Study: 2673080
Drug: Dried chopped
Normalized name: peptone,dried
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried chopped feverfew (70‐86 mg)
Study: 24105072
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg ethinyl-estradiol (EE) with 3 mg drospirenone
Study: 24105072
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg ethinyl-estradiol (EE) with 3 mg drospirenone
Study: 24105072
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (20 μg EE and 30 μg EE)
Study: 20439553
Drug: Concord grape
Normalized name: Concord Grape
DrugBank: Concord grape (DB10875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concord grape juice (CGJ) 480 mL daily for 12 weeks
Study: 20439553
Drug: Substitute grape-flavored
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substitute grape-flavored drink (SGD) 480 mL daily for 12 weeks
Study: 17255252
Drug: NaDCC tablets
Normalized name: Mcla-128 (igg1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) activity targeting her2 and her3 receptors.)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaDCC tablets
Study: 14999359
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium (660 mg daily, 440 mg for patients ≥65 years)
Study: 14999359
Drug: Acetaminophen (4000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (4000 mg daily)
Study: 11682416
Drug: Tramadol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 0.5 mg/kg
Study: 11682416
Drug: Amitriptyline 15
Normalized name: amitriptyline 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 15 or 20 mg
Study: 7948797
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine (0.2 mg/kg) and scopolamine (0.01 mg/kg)
Study: 7948797
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.75 mg/kg)
Study: 3283766
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with Flutamide and LHRH agonist [D‐Trp]LHRH ethylamide
Study: 3283766
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with Flutamide
Study: 20820150
Drug: Premedication consisting
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premedication consisting of 7.5 mg midazolam, 50 mg diclofenac, 1000 mg acetaminophen (orally) and fentanyl (intravenously)
Study: 11817992
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose polyethylene glycol 3350 plus electrolytes (PEG+E)
Study: 10632776
Drug: finasteride 5
Normalized name: finasteride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: finasteride 5 mg daily for 24 months
Study: 10632776
Drug: placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo daily for 24 months
Study: 2019938
Drug: Nebulized salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized salbutamol (0.10 mg/kg in 2 ml 0.9% saline solution)
Study: 2019938
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline solution placebo
Study: 6814298
Drug: Intravenous nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitroglycerin (IV NTG) 0.5 micrograms/kg/min
Study: 6814298
Drug: Intravenous nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitroglycerin (IV NTG) 0.1 micrograms/kg/min
Study: 30765737
Drug: DHA-CHO-VE multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-CHO-VE multivitamin treatment (DHA, choline, vitamin E)
Study: 30765737
Drug: DHA-VD multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-VD multivitamin treatment (DHA, vitamin D)
Study: 30541606
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg lidocaine + 2 mg CPC
Study: 30541606
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg lidocaine + 2 mg CPC
Study: 27026311
Drug: Rectal V38
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal V38 (≥2.0 cm³)
Study: 29499622
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of anticoagulants
Study: 27026311
Drug: Rectal V38
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal V38 < 2.0 cm³ with anticoagulants or V38 ≥ 2.0 cm³ plus 1 other risk factor
Study: 22272750
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate (oral treatment for four weeks)
Study: 15150185
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g once a day
Study: 10955752
Drug: Regular inhaled
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular inhaled terbutaline (500-1000 microg four times daily)
Study: 1614781
Drug: Rice, soy-protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice, soy-protein isolate, corn syrup solids, and vegetable oil (group RS)
Study: 31206571
Drug: Pulpectomy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulpectomy treatment with Maisto‐Capurro paste (G1)
Study: 31206571
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with 3Mix‐MP paste (G2)
Study: 24520674
Drug: Yuleshu oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yuleshu oral mixture combined with conventional therapy
Study: 17239325
Drug: 5‐hydroxytryptamine type
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐hydroxytryptamine type 3 receptor antagonists
Study: 8286805
Drug: Clindamycin 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 2% vaginal cream
Study: 7498208
Drug: Prolonged sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged sequential inflations (3 to 5 inflations of 3 to 5 min each, total duration > or = 12 min, group 1, n = 20 lesions)
Study: 7498208
Drug: Standard sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard sequential inflations (3 to 5 inflations of < or = 1 min each, total duration < or = 3 min, group 2, n = 24 lesions)
Study: 2188696
Drug: Day patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day patient treatment
Study: 7040497
Drug: Bumetanide (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide (0.5 mg intravenous)
Study: 7040497
Drug: Furosemide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (20 mg intravenous)
Study: 28404973
Drug: L-asparaginase, cisplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-asparaginase, cisplatin, etoposide, and dexamethasone (LVDP) plus concurrent chemoradiotherapy (CCRT)
Study: 24339273
Drug: Group Training
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Training (GT) of the Otago Exercise Program (OEP) performed twice weekly for 12 weeks
Study: 23326865
Drug: Perindopril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (5 mg)
Study: 23326865
Drug: Perindopril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (10 mg)
Study: 19236441
Drug: Insulin injection
Normalized name: diluent for insulin lispro and regular insulin INJECTION VIAL (ML)
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin injection into normal tissue
Study: 19236441
Drug: Insulin injection
Normalized name: diluent for insulin lispro and regular insulin INJECTION VIAL (ML)
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin injection into lipohypertrophic tissue
Study: 19236441
Drug: Injection sites
Normalized name: IV SET W/2 INJECTION SITES 15GTTS/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection sites (normal vs lipohypertrophic)
Study: 18444444
Drug: Dronabinol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol (10 mg)
Study: 8053585
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at target blood concentration 2 micrograms/ml
Study: 8053585
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at target blood concentration 4 micrograms/ml
Study: 2903191
Drug: Intensified antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified antihypertensive treatment aiming to lower diastolic blood pressure to less than or equal to 80 mmHg.
Study: 2903191
Drug: Unchanged antihypertensive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unchanged antihypertensive treatment.
Study: 22890369
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone (IVTA) 4 mg/0.1 mL
Study: 19809604
Drug: Pharmacologic thromboprophylaxis
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic thromboprophylaxis with low‐molecular‐weight heparins, vitamin K antagonists, or fondaparinux
Study: 16996338
Drug: L-EUS
Normalized name: chlorine dioxide
DrugBank: Chlorine dioxide (DB12453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-EUS
Study: 14584962
Drug: Deramciclane 30
Normalized name: Deramciclane
DrugBank: Deramciclane (DB06512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deramciclane 30 mg intravenous administration
Study: 14584962
Drug: Deramciclane oral
Normalized name: Deramciclane
DrugBank: Deramciclane (DB06512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deramciclane oral administration (solution)
Study: 14584962
Drug: Deramciclane oral
Normalized name: Deramciclane
DrugBank: Deramciclane (DB06512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deramciclane oral administration (tablet)
Study: 7599448
Drug: Fluoride treatment
Normalized name: 60 Second 1.23% Fluoride Treatment Dental Gel
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoride treatment (75 mg NaF/day)
Study: 360272
Drug: Lidocaine administered
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine administered as a bolus intra-arterially prior to contrast media injections
Study: 360272
Drug: Lidocaine mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine mixed with contrast agent (2 mgm of lidocaine with each ml of contrast agent)
Study: 30824252
Drug: Tablet-facilitated TF-CBT
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet-facilitated TF-CBT
Study: 28382880
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no adjunctive maneuvers)
Study: 25223583
Drug: CPX-351 (cytarabine:
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPX-351 (cytarabine: daunorubicin) liposome injection
Study: 25223583
Drug: Control salvage
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control salvage treatment (investigators' choice of first salvage chemotherapy)
Study: 15370939
Drug: Preparation/Action stages
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation/Action stages of change
Study: 11349750
Drug: Overall relationship
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall relationship between prescription orders filled/hour and risk of dispensing errors
Study: 23559219
Drug: Atypical antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotic exposure
Study: 23559219
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antipsychotic exposure)
Study: 20622680
Drug: Intermittent Sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent Sequential Compression Device (SCD)
Study: 19531453
Drug: Bioimmunochemotherapy (BCT)
Normalized name: Pegylated recombinant human arginase i bct-100
DrugBank: Pegylated Recombinant Human Arginase I (DB16282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioimmunochemotherapy (BCT) with cisplatin 20 mg/m² i.v. days 1,4; dacarbazine 800 mg/m² i.v. day 1; vinblastine 1.5 mg/m² i.v. days 1,4; IL-2 9 MIU/m² s.c. days 5,8; IFN-alpha-2b 5 MIU/m² s.c. days 5,8,11,13,15; supported by G-CSF and antibiotics
Study: 9783758
Drug: Meloxicam (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam (7.5 mg once daily for 28 days)
Study: 9783758
Drug: Piroxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (20 mg once daily for 28 days)
Study: 28042979
Drug: L-PRF and
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-PRF and BMP-2
Study: 25076119
Drug: Prehospital TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prehospital TXA infusion
Study: 16375658
Drug: 1,000 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg/day of divalproex sodium
Study: 16375658
Drug: 1,500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,500 mg/day of divalproex sodium
Study: 11973443
Drug: Transdermal E2/LNG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2/LNG (E2 0.045 mg/day with 0.030 and 0.040 mg/day LNG)
Study: 11973443
Drug: Transdermal E2/LNG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2/LNG (E2 0.045 mg/day with 0.015, 0.030, and 0.040 mg/day LNG)
Study: 11973443
Drug: Transdermal E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2 0.045 mg/day